Future Fund LLC Has $3.58 Million Stock Position in Globus Medical, Inc. $GMED

Future Fund LLC raised its stake in shares of Globus Medical, Inc. (NYSE:GMED) by 41.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 41,011 shares of the medical device company’s stock after purchasing an additional 11,988 shares during the quarter. Globus Medical accounts for 1.2% of Future Fund LLC’s portfolio, making the stock its 18th largest holding. Future Fund LLC’s holdings in Globus Medical were worth $3,581,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. SBI Securities Co. Ltd. boosted its holdings in Globus Medical by 98.2% during the fourth quarter. SBI Securities Co. Ltd. now owns 337 shares of the medical device company’s stock valued at $29,000 after purchasing an additional 167 shares in the last quarter. Advisory Services Network LLC acquired a new stake in Globus Medical during the third quarter valued at approximately $26,000. EverSource Wealth Advisors LLC boosted its holdings in Globus Medical by 74.3% during the second quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company’s stock valued at $27,000 after purchasing an additional 197 shares in the last quarter. Larson Financial Group LLC boosted its holdings in Globus Medical by 83.4% during the fourth quarter. Larson Financial Group LLC now owns 532 shares of the medical device company’s stock valued at $46,000 after purchasing an additional 242 shares in the last quarter. Finally, Parallel Advisors LLC boosted its holdings in Globus Medical by 45.1% during the third quarter. Parallel Advisors LLC now owns 557 shares of the medical device company’s stock valued at $32,000 after purchasing an additional 173 shares in the last quarter. 95.16% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on GMED. Zacks Research raised Globus Medical from a “hold” rating to a “strong-buy” rating in a report on Tuesday, March 3rd. Needham & Company LLC boosted their target price on Globus Medical from $114.00 to $117.00 and gave the stock a “buy” rating in a report on Friday, May 8th. Royal Bank Of Canada boosted their target price on Globus Medical from $115.00 to $120.00 and gave the stock an “outperform” rating in a report on Friday, May 8th. Wells Fargo & Company reduced their target price on Globus Medical from $104.00 to $103.00 and set an “overweight” rating on the stock in a report on Friday, May 8th. Finally, Weiss Ratings reissued a “hold (c+)” rating on shares of Globus Medical in a report on Wednesday, April 15th. Two investment analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $106.36.

Globus Medical Stock Performance

NYSE:GMED opened at $82.00 on Friday. The stock’s fifty day moving average price is $87.01 and its two-hundred day moving average price is $88.41. Globus Medical, Inc. has a 52-week low of $51.79 and a 52-week high of $101.40. The company has a market cap of $11.13 billion, a price-to-earnings ratio of 19.07, a P/E/G ratio of 1.70 and a beta of 1.00.

Globus Medical (NYSE:GMED) last posted its quarterly earnings data on Thursday, May 7th. The medical device company reported $1.12 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.92 by $0.20. Globus Medical had a return on equity of 13.46% and a net margin of 18.92%.The firm had revenue of $759.85 million for the quarter, compared to the consensus estimate of $740.35 million. During the same quarter in the prior year, the business earned $0.68 EPS. The business’s revenue for the quarter was up 27.0% compared to the same quarter last year. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. On average, equities analysts predict that Globus Medical, Inc. will post 4.74 EPS for the current fiscal year.

Globus Medical Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.